Gainers
- HCW Biologics HCWB shares rose 251.2% to $0.98 during Monday's pre-market session. The market value of their outstanding shares is at $43.5 million.
- GH Research GHRS shares rose 90.45% to $20.19. The company's market cap stands at $1.0 billion.
- Invivyd IVVD stock moved upwards by 24.68% to $0.45. The company's market cap stands at $53.3 million.
- Quince Therapeutics QNCX shares increased by 11.8% to $1.8. The company's market cap stands at $79.2 million.
- Redhill Biopharma RDHL shares rose 10.67% to $6.54. The market value of their outstanding shares is at $8.3 million.
- IDEXX Laboratories IDXX shares increased by 10.41% to $466.0. The market value of their outstanding shares is at $38.1 billion. The company's, Q4 earnings came out today.
Losers
- Viracta Therapeutics VIRX shares decreased by 43.6% to $0.09 during Monday's pre-market session. The company's market cap stands at $3.3 million.
- Procaps Gr PROC shares declined by 41.11% to $0.94. The company's market cap stands at $105.7 million.
- Annovis Bio ANVS shares decreased by 18.07% to $3.99. The market value of their outstanding shares is at $55.0 million.
- Elutia ELUT shares declined by 14.6% to $2.75. The market value of their outstanding shares is at $95.0 million.
- Senseonics Holdings SENS shares fell 12.81% to $0.84. The market value of their outstanding shares is at $498.7 million.
- BioCardia BCDA stock declined by 10.94% to $2.2. The company's market cap stands at $10.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/
This article was generated by Benzinga's automated content engine and reviewed by an editor.
BCDABioCardia Inc
$2.38-3.64%
ELUTElutia Inc
$2.75-14.6%
GHRSGH Research PLC
$18.0069.8%
HCWBHCW Biologics Inc
$0.6190122.5%
IDXXIDEXX Laboratories Inc
$471.3411.7%
IVVDInvivyd Inc
$0.9989179.3%
PROCProcaps Group SA
$1.18-25.6%
QNCXQuince Therapeutics Inc
$1.59-1.12%
RDHLRedhill Biopharma Ltd
$5.88-0.50%
SENSSenseonics Holdings Inc
$0.8910-7.26%
VIRXViracta Therapeutics Inc
$0.0735-51.5%
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in